Keep up to date with our latest partnering deals and highlights
Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.
- Thursday, 21 March 2013
- AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.
- Tuesday, 15 January 2013
- AstraZeneca announces changes to Senior Executive Team AstraZeneca today unveiled changes to its executive leadership team. The new, expanded membership of AstraZeneca’s Senior Executive Team, which comes into effect immediately, includes increased representation of the company’s scientific expertise, key products and key markets.
- Monday, 14 January 2013
- AstraZeneca and Vanderbilt University collaborate to develop novel treatments for major brain disorders Today AstraZeneca and Vanderbilt University announced they have signed a research collaboration agreement to identify candidate drugs aimed at treating psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer’s disease and schizophrenia.